InsiderPulse| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-27 | 2026-03-31 | Manning Meredith | Chief Commercial Officer | Sale | 7,522 | $30.44 | $229K | 64.5K | View ↗ | |
| 2026-03-27 | 2026-03-31 | Huang Michael F. | Sr. VP of Clinical Development | Sale | 6,582 | $30.44 | $200K | 39.8K | View ↗ |
| Metric | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|
| Research and development | $25.2M+65.0% | $15.3M-28.8% | $21.5M-7.5% | $23.2M |
| General and administrative | $13.5M+36.9% | $9.8M-8.9% | $10.8M+23.4% | $8.8M |
| Change in fair value of contingent consideration | $2.7M+481.2% | -$712K+2.6% | -$731K-116.8% | $4.3M |
| Total operating expenses | $41.4M+69.6% | $24.4M-22.6% | $31.5M-13.1% | $36.3M |
| Operating loss | -$41.4M-69.6% | -$24.4M+22.6% | -$31.5M+13.1% | -$36.3M |
| Change in fair value of warrant liability | -$182K-706.7% | $30K-94.1% | $508K-95.6% | $11.6M |
| Interest income | $2.6M+759.3% | $300K+172.7% | $110K+746.2% | $13K |
| Total other income (expense), net | $2.4M+626.1% | $330K-46.6% | $618K-94.7% | $11.7M |
| Net loss | -$39.0M-62.0% | -$24.1M+22.1% | -$30.9M-25.5% | -$24.6M |
| Net loss per common share basic | -$2K+17.8% | -$3K+50.6% | -$6K | — |
| Net loss per common share diluted | -$2K+17.8% | -$3K+50.6% | -$6K | — |
| Weighted-average common shares outstanding used to calculate basic net loss per common share | $16.49B+96.4% | $8.40B+57.9% | $5.32B | — |
| Weighted-average common shares outstanding used to calculate diluted net loss per common share | $16.49B+96.4% | $8.40B+57.9% | $5.32B | — |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics
Soleno Merger With Neurocrine Puts Profitability And Valuation In Focus
Neurocrine Biosciences: Core Business On Track, Soleno Deal Adds Risky Upside
Neurocrine Biosciences Q1 Earnings Call Highlights